The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data

Achan, J.; Menendez, C.; Adam, I.; Arinaitwe, E.; Bassat, Q.; Guerin, Pj J.; Hay, Si I.; Borrmann, S.; Ashley, Ea A.; Hien, Tt T.; Janssens, B.; Dahal, P.; Awab, Gr R.; Marsh, K.; Kamya, Mr R.; Mayxay, M.; Bousema, Jan Teun; D'Alessandro, U.; Karema, C.; Ba,; Mens, Pf F.; Meremikwu, M.; Davis, Tme M. E.; Karunajeewa, Ha A.; Barnes, Ki I.; Moreira, C.; Menéndez, C.; Mueller, I.; Dondorp, Am M.; Kone, M.; Nabasumba, C.; Dorsey, G.; Nambozi, M.; Lell, Bertrand; Drakeley, Cj J.; Ndiaye, J.-L.; Fanello, Ci I.; Newton, Pn N.; Faye, B.; Flegg, Ja A.; Nguyen, T.-N.; Gaye, O.; Gething, Pw W.; Nosten, F.; Gonzalez, R.; Talisuna, Ao O.; Nsanzabana, C.; Tarning, J.; Omar, Sa A.; Ouedraogo, J.-B.; Tjitra, E.; Penali, Lk K.; Tine, Rck C. K.; Pene, M.; Tinto, H.; Phyo, Ap P.; Valecha, N.; Piola, P.; Van Herp, M.; Price,; Van Vugt, M.; Sasithon, P.; Rosenthal, Pj J.; White, Nj J.; Same-Ekobo, A.; Woodrow, Cj J.; Grp, Wwarndps; Sawa, P.; Schallig, Hdfh D. F. H.; Yavo, W.; Shekalaghe, Sa A.; Yeka, A.; Sibley, Ch H.; Group, WorldWide Antimalarial Resistance Network (WWARN) DP Study; Smith, J.; Zongo, I.; Smithuis, F.; Some, Af F.; Stepniewska, Kasia; Group, W. A. R. N. W. D. S.; A.-L., E.; Study Group, Dp

Tools

The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data

Journal article published in 2013 by J. Achan, C. Menendez, I. Adam, E. Arinaitwe, Q. Bassat, Pj J. Guerin, Si I. Hay, S. Borrmann, Ea A. Ashley, Tt T. Hien, B. Janssens, P. Dahal, Gr R. Awab, K. Marsh, Mr R. Kamya and other authors.

This paper is available in a repository.

Full text: Download

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload

Abstract

Background:Dihydroartemisinin-piperaquine (DP) is increasingly recommended for antimalarial treatment in many endemic countries; however, concerns have been raised over its potential under dosing in young children. We investigated the influence of different dosing schedules on DP's clinical efficacy.Methods and Findings:A systematic search of the literature was conducted to identify all studies published between 1960 and February 2013, in which patients were enrolled and treated with DP. Principal investigators were approached and invited to share individual patient data with the WorldWide Antimalarial Resistance Network (WWARN). Data were pooled using a standardised methodology. Univariable and multivariable risk factors for parasite recrudescence were identified using a Cox's regression model with shared frailty across the study sites. Twenty-four published and two unpublished studies (n = 7,072 patients) were included in the analysis. After correcting for reinfection by parasite genotyping, Kaplan-Meier survival estimates were 97.7% (95% CI 97.3%-98.1%) at day 42 and 97.2% (95% CI 96.7%-97.7%) at day 63. Overall 28.6% (979/3,429) of children aged 1 to 5 years received a total dose of piperaquine below 48 mg/kg (the lower limit recommended by WHO); this risk was 2.3-2.9-fold greater compared to that in the other age groups and was associated with reduced efficacy at day 63 (94.4% [95% CI 92.6%-96.2%], p

Links

Tools

The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data

Abstract